.png){kind=small}
.png){kind=small}
BackTable / VI / Podcast / Episode #92
Interventional Oncology in Private Practice (Part 2)
with Dr. Justin Lee
Interventional Radiologist Justin Lee tells us about his approach to treatment of Hepatocellular Carcinoma (HCC), including how this has changed over his years in private practice. This is part two of a two part series.
This podcast is supported by:
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2020, October 29). Ep. 92 – Interventional Oncology in Private Practice (Part 2) [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Synopsis
In this episode, Dr. Justin Lee joins Dr. Christopher Beck to discuss hepatocellular carcinoma (HCC) and interventional oncology in private practice. Dr. Lee tells us how he frames his HCC patients and works with medical oncologists for treatment plans and procedures.
We talk about the importance of IR bringing cases to the tumor board, the evolution of cases involving ablation, and why Dr. Lee started moving towards radioembolization (Y90). We review how to approach HCC cases while working with medical oncologists.
We examine the differences between using resin and glass for radioembolization and when they should be used. Dr. Lee shares why IR should start looking into arterial drug delivery for immunotherapies.
Resources
NEJM: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
https://www.nejm.org/doi/10.1056/NEJMoa1915745
This paper, mentioned by Dr. Lee, discusses the third phase of an HCC trial.
The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Up Next
Articles
Topics
